The American Journal of Managed Care5d
FDA Approves Expanded Indication of Eculizumab for Pediatric Generalized Myasthenia Gravis
The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the ...
Yahoo Finance10d
FDA Approves Expanded Use of Eculizumab (Soliris) for Pediatric Myasthenia Gravis, Bringing New Treatment Options for Children
approval of the expanded indication of Alexion/AstraZeneca’s eculizumab (Soliris) for pediatric patients aged six years and older with generalized myasthenia gravis (gMG) who are anti ...
Business Insider10d
FDA Approves Expanded Use of Eculizumab (Soliris) for Pediatric Myasthenia Gravis, Bringing New Treatment Options for Children
New York, March 10, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s ...
pharmaphorum1d
Amgen's Soliris biosimilar clears phase 3, but won't launch until 2025
Alexion already has a newer product to defend the franchise in Ultomiris (ravulizumab), a longer-acting C5 inhibitor that requires dosing every eight weeks while Soliris is given every two weeks.
Healio8d
FDA approves Soliris for patients aged 6 years and up with generalized myasthenia gravis
The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and ...
The Bakersfield Californian10d
FDA Approves Expanded Use of Eculizumab (Soliris) for Pediatric Myasthenia Gravis, Bringing New ...
The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s eculizumab ( ...
pharmaphorum5d
Soliris, the world’s most expensive drug: will NICE judge it affordable?
NICE and Alexion not backing down The Soliris appraisal has largely been conducted via complex health economic arguments and counter arguments, but NICE's HST committee and representatives came ...